Novo Nordisk to Seek China Approval for Oral Wegovy

Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug Wegovy, according to sources familiar with the matter. The move is part of the company's strategy to expand its presence in the world's second-largest pharmaceutical market.

Details of the Regulatory Action

The company intends to submit an application to China's National Medical Products Administration (NMPA) for the oral formulation of Wegovy, which contains the active ingredient semaglutide. The exact timeline for submission and potential approval has not been disclosed.

Company's Position

Novo Nordisk has not officially commented on the plans, but has previously highlighted China as a key market for its obesity portfolio. The injectable version of Wegovy is already approved in several countries.

Precedents and Context

China's rising obesity rates present a significant opportunity for drugmakers. An oral formulation could give Novo Nordisk a competitive edge over rivals like Eli Lilly (LLY), which is also developing oral obesity treatments.

Potential Financial Impact

If approved, the oral Wegovy could significantly boost Novo Nordisk's revenue from the Chinese market. However, regulatory hurdles and competition remain challenges.